Bangladesh - anglais - DGDA (Directorate General of Drug Administration)

popular pharmaceuticals ltd. - calcium (coral calcium) + vitamin d3 - tablet - 500 mg + 200 iu

Bangladesh - anglais - DGDA (Directorate General of Drug Administration)

biogen pharmaceuticals ltd. - calcium (coral calcium) + vitamin d3 - tablet - 500 mg + 200 iu

Bangladesh - anglais - DGDA (Directorate General of Drug Administration)

biogen pharmaceuticals ltd. - calcium (coral calcium) + vitamin d3 - tablet - 600 mg + 400 iu

Bangladesh - anglais - DGDA (Directorate General of Drug Administration)

rangs pharmaceuticals ltd. - calcium (coral calcium) + vitamin d3 - tablet - 500 mg + 200 iu

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bio-science marketing sdn. bhd. - coral calcium; vitamin k2; vitamin d3 (cholecalciferol) -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

tachisan enterprise (m) sdn. bhd. - coral calcium; vitamin k2; dl-alpha tocopheryl acetate; vitamin d3 (cholecalciferol) -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

coral cay health pty ltd - biotin,calcium pantothenate,choline bitartrate,cyanocobalamin,folic acid,inositol,magnesium oxide,nicotinamide,pyridoxine hydrochloride,riboflavin,thiamine hydrochloride,zinc sulfate monohydrate -

Union européenne - anglais - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Israël - anglais - Ministry of Health

medison pharma ltd - ivabradine as hydrochloride - film coated tablets - ivabradine as hydrochloride 7.5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Israël - anglais - Ministry of Health

medison pharma ltd - ivabradine as hydrochloride - film coated tablets - ivabradine as hydrochloride 5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.